- Home
- NGVC vs DNTH Comparison
NGVC vs DNTH Comparison
Compare NGVC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGVC
- DNTH
- Stock Information
- Founded
- NGVC 1955
- DNTH 2015
- Country
- NGVC United States
- DNTH United States
- Employees
- NGVC N/A
- DNTH N/A
- Industry
- NGVC Food Chains
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NGVC Consumer Staples
- DNTH Health Care
- Exchange
- NGVC Nasdaq
- DNTH Nasdaq
- Market Cap
- NGVC 865.7M
- DNTH 724.8M
- IPO Year
- NGVC 2012
- DNTH N/A
- Fundamental
- Price
- NGVC $40.19
- DNTH $18.14
- Analyst Decision
- NGVC
- DNTH Strong Buy
- Analyst Count
- NGVC 0
- DNTH 8
- Target Price
- NGVC N/A
- DNTH $54.33
- AVG Volume (30 Days)
- NGVC 136.3K
- DNTH 362.0K
- Earning Date
- NGVC 05-08-2025
- DNTH 03-11-2025
- Dividend Yield
- NGVC 1.18%
- DNTH N/A
- EPS Growth
- NGVC 33.38
- DNTH N/A
- EPS
- NGVC 1.56
- DNTH N/A
- Revenue
- NGVC $1,270,056,000.00
- DNTH $6,235,000.00
- Revenue This Year
- NGVC $1.32
- DNTH N/A
- Revenue Next Year
- NGVC N/A
- DNTH N/A
- P/E Ratio
- NGVC $24.44
- DNTH N/A
- Revenue Growth
- NGVC 9.31
- DNTH 120.63
- 52 Week Low
- NGVC $15.82
- DNTH $17.50
- 52 Week High
- NGVC $50.91
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- NGVC 52.22
- DNTH 36.91
- Support Level
- NGVC $37.03
- DNTH $17.50
- Resistance Level
- NGVC $39.61
- DNTH $20.45
- Average True Range (ATR)
- NGVC 1.61
- DNTH 1.67
- MACD
- NGVC 0.41
- DNTH -0.22
- Stochastic Oscillator
- NGVC 88.48
- DNTH 10.44
About NGVC Natural Grocers by Vitamin Cottage Inc.
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.